Accolate
(Zafirlukast)Phase 2Small molecule
Alnylam PharmaceuticalsZafirlukast is a medication that helps prevent asthma symptoms by blocking substances in the body that cause airway swelling and tightening. It's used as a preventative treatment to help control asthma, not to treat sudden asthma attacks.[1] Accolate is currently being investigated across 2 indications[3], with its most advanced program in Phase 2.[1]
Accolate is one of 47 small molecule programs targeting Contracture. It is currently in Phase 2.
2
Indications
4
Total Trials
1
Active Trials
46
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
836 competitors in Ovarian Cancer
#DrugCompanyPhaseTrials
1Femara
NovartisPhase 3
Tecentriq
RochePhase 3
Veliparib
AbbViePhase 3
H2 Receptor Antagonist
Merck & Co.Phase 3
Chiauranib
CChipscreen Biosciences, Ltd.
Phase 3
Investigator's Choice of Chemotherapy
CCSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 3
H1 Receptor Antagonist
Merck & Co.Phase 3
Masitinib
AAB Science
Phase 3
Karenitecin
BBioNumerik Pharmaceuticals, Inc.
Phase 3
VB-111
VVascular Biogenics Ltd. operating as VBL Therapeutics
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Acute Lymphoblastic Leukemia1 trial
Crossover Study of Zafirlukast in Preventing Allergen-induced Signs and Symptoms in Response to Cat Dander Challenge
Not yet recruiting·—·Phase 2·NCT06069063·12 enrolled
Contracture1 trial
Labor1 trial
Bioequivalence Study of Zafirlukast Tablets 20 mg of Dr. Reddy's Laboratories Limited Under Fasting Condition
Completed·—·Phase 1·NCT01283061·44 enrolled
Ovarian Cancer1 trial
Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer
Completed·—·Phase 2·NCT04339140·5 enrolled
Regulatory
FDA Approval Timeline[4]
Sep 17, 1999
ACCOLATE
NDA NDA020547
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Zafirlukast. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company